Increasing Lithium to 900mg is Appropriate with Proper Monitoring
Yes, increasing lithium from 600mg to 900mg is appropriate in this clinical scenario, but lithium levels should be checked 5-7 days after the dose increase to ensure therapeutic levels and monitor for toxicity 1.
Rationale for Lithium Augmentation
This patient presents with treatment-resistant depression (TRD) and a history of suicide attempt—two critical factors that make lithium augmentation particularly appropriate:
Evidence for Lithium in Treatment-Resistant Depression
Lithium augmentation of antidepressants is strongly supported by evidence 2. When added to antidepressants like fluoxetine, lithium demonstrates significantly greater efficacy than placebo (p<0.0001) 2. This patient is already on fluoxetine 80mg (maximum dose), making augmentation the logical next step rather than switching agents 3.
Critical Anti-Suicidal Properties
Lithium has unique and substantial anti-suicidal effects that are particularly relevant given this patient's history 4. Meta-analyses demonstrate that lithium maintenance treatment reduces suicide attempt recurrence 8.6-fold in adults with major affective disorders 4. These effects may be due to lithium's central serotonin-enhancing properties and appear to be unique among mood stabilizers 4. The 2025 VA/DoD guidelines note insufficient evidence to make a definitive recommendation on lithium for suicide risk reduction, but acknowledge the supporting evidence 5.
Dosing and Monitoring Protocol
Dose Increase Strategy
- The increase from 600mg to 900mg represents a 50% dose escalation, which is reasonable for achieving therapeutic lithium levels (typically 0.6-1.2 mEq/L for augmentation)
- This dose is within standard therapeutic ranges used in clinical trials 2
Timing of Lithium Level Check
Check lithium levels 5-7 days after the dose change 1. This timing allows:
- Achievement of steady-state concentrations (lithium has a 24-hour half-life, so steady state occurs in approximately 5 days)
- Early detection of potential toxicity
- Dose adjustment if levels are subtherapeutic or supratherapeutic
Important Drug Interaction Considerations
Monitor closely for lithium toxicity given the fluoxetine interaction 1. The FDA label specifically warns that there have been reports of both increased and decreased lithium levels when used concomitantly with fluoxetine, and cases of lithium toxicity have occurred 1. This makes the 5-day level check even more critical.
Clinical Monitoring Requirements
Given the suicide risk and medication changes, implement the following:
- Immediate monitoring: Assess patient status within 1-2 weeks of any dose change for worsening depression, suicidal ideation, agitation, or unusual behavioral changes 3
- Lithium-specific monitoring: Check for signs of lithium toxicity (tremor, confusion, ataxia, polyuria, polydipsia)
- Renal function: Ensure baseline and periodic creatinine monitoring, as lithium is renally excreted
- Thyroid function: Monitor TSH periodically, as lithium can cause hypothyroidism
Common Pitfalls to Avoid
Inadequate plasma lithium levels: Studies show difficulty achieving adequate plasma lithium levels is common 6. Don't assume 900mg will be sufficient—adjust based on serum levels and clinical response
Premature discontinuation: If lithium is discontinued, there is a 7-fold increase in suicide attempt rate and 9-fold increase in suicide rate 4. Any future discontinuation must be gradual and carefully monitored
Overlooking the high-risk period: The risk for suicide attempts is greatest during the first 1-2 months of antidepressant treatment 3. This patient requires close monitoring regardless of the lithium increase
Ignoring the buspirone: At only 5mg TID (15mg total daily), buspirone is at a subtherapeutic dose for anxiety augmentation (typical range 30-60mg/day). Consider whether this medication is providing benefit or could be optimized
Expected Timeline for Response
- Lithium augmentation response: Typically occurs within 2-4 weeks if effective 6, 2
- Reassessment point: If no adequate response within 6-8 weeks of the lithium increase, consider additional treatment modifications 3
Safety Considerations
Lithium requires careful third-person supervision due to lethal overdose potential 4. Ensure:
- Prescriptions are written for the smallest quantity consistent with good patient management
- Family/caregivers are educated about signs of toxicity
- Lethal means restriction is addressed (firearms, medications)
The combination of treatment-resistant depression and prior suicide attempt makes this a high-stakes clinical situation where lithium's dual benefits—augmenting antidepressant response and reducing suicide risk—are particularly valuable.